Sofosbuvir-Velpatasvir Coupons & Prices

Looking for a sofosbuvir/velpatasvir coupon? Sofosbuvir/velpatasvir (brand name Epclusa) is an FDA-approved direct-acting antiviral used to cure chronic hepatitis C, and because a generic version of Epclusa is available, pricing can vary widely from one pharmacy to the next. Rx.com compares prices across more than 60,000 U.S. pharmacies so you can see where sofosbuvir/velpatasvir costs less near you — enter your ZIP code above to see today's price.

What Is Sofosbuvir/Velpatasvir (Epclusa) and How Does It Work?

Sofosbuvir/velpatasvir is a combination direct-acting antiviral (an NS5B polymerase inhibitor paired with an NS5A inhibitor) that treats chronic hepatitis C virus (HCV) infection. It's FDA-approved for genotypes 1 through 6 in adults and children 3 years and older, as tablets or oral pellets, in patients without cirrhosis or with compensated (mild) cirrhosis. In patients with decompensated (advanced) cirrhosis, it's used together with ribavirin.

Treatment is typically a once-daily tablet for 12 weeks. This is a finite, curative regimen rather than a drug taken long-term — reported cure (sustained virologic response) rates exceed 95% across genotypes.

Sofosbuvir/Velpatasvir Cost and Coupon Savings

Many people searching for a "sofosbuvir/velpatasvir coupon" are trying to manage the cost of a 12-week hepatitis C cure. What you pay — with or without insurance — depends heavily on your coverage, your plan's specialty-drug tier, and which pharmacy fills the prescription, since pharmacy pricing for this medication varies significantly. Because a generic version of Epclusa is available, comparing pharmacies is worth doing before you fill. Rx.com checks pricing across more than 60,000 pharmacies nationwide — enter your ZIP code above to see today's price near you.

The brand manufacturer also runs its own savings program for eligible patients; visit epclusa.com directly for current eligibility and terms, which vary and are subject to change.

Sofosbuvir/Velpatasvir vs. Other Hepatitis C Treatments

Sofosbuvir/velpatasvir is one of several direct-acting antiviral options for hepatitis C. It contains sofosbuvir as one of its two active ingredients, and it's used with ribavirin specifically in patients with decompensated cirrhosis. Other combination regimens your doctor may consider, depending on HCV genotype and treatment history, include ledipasvir/sofosbuvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir.

Only your prescribing provider can determine which regimen is right for your genotype, liver status, and prior treatment history — this comparison is informational, not a substitute for medical advice.

Safety Information for Sofosbuvir/Velpatasvir

Sofosbuvir/velpatasvir carries a boxed warning for hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV, which has caused fulminant hepatitis, liver failure, and death in some cases. All patients must be tested for current or prior HBV infection before starting treatment, and those coinfected with HBV need monitoring during and after therapy.

• Serious, symptomatic slow heart rate (bradycardia) can occur when taken with amiodarone, especially alongside a beta-blocker or with existing heart disease — this combination is generally avoided and amiodarone is not recommended.
• Not recommended with strong P-gp inducers such as rifampin or St. John's wort, which can significantly reduce how well the medication works.
• Taking it together with rosuvastatin significantly raises rosuvastatin levels in the blood; the label limits the rosuvastatin dose to 10 mg daily when combined with sofosbuvir/velpatasvir, with monitoring for muscle-related side effects (myopathy/rhabdomyolysis).
• Common side effects include headache, fatigue, and nausea.
• Sofosbuvir/velpatasvir is not a controlled substance.

This is general safety information, not medical advice — talk with your doctor or pharmacist about your specific health history before starting treatment.